Cellular Immunotherapy for Neuroblastoma: A Review of Current Vaccine and Adoptive T Cell Therapeutics

Author(s): C. U. Louis, M. K. Brenner

Journal Name: Current Pharmaceutical Design

Volume 15 , Issue 4 , 2009

Become EABM
Become Reviewer
Call for Editor


Immunotherapy is an attractive option for patients with high risk neuroblastoma due to their poor long-term survival rates after conventional treatment. Neuroblastoma cells are derived from the embryonic neural crest and therefore express tumor antigens not widely seen in normal cells, making them potential targets for immunologic attack. There is already considerable experience with monoclonal antibodies that target these tumor associated antigens, and in this review we focus on more exploratory approaches, using tumor vaccines and adoptive transfer of tumor-directed T cells.

Keywords: Neuroblastoma, immunotherapy, adoptive T cell transfer, chimeric antigen receptors, vaccine trials

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2009
Published on: 01 March, 2012
Page: [424 - 429]
Pages: 6
DOI: 10.2174/138161209787315765
Price: $65

Article Metrics

PDF: 5